CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations
- PMID: 35401003
- PMCID: PMC8986482
- DOI: 10.2147/NDT.S355985
CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations
Abstract
Background: It has been suggested that the pharmacogenomic response to antipsychotics in schizophrenia patients partially contributed by drug metabolism enzyme polymorphism, including P450 2D6 (CYP2D6). However, CYP2D6 gene polymorphism across populations is largely unknown.
Materials and methods: Here, we investigated the differences of CYP2D6 gene polymorphism between Chinese Han and Tibetan schizophrenia patients. We analyzed five CYP2D6 gene related polymorphic locus in 103 patients with schizophrenia, including 60 Han ethnicity and 43 of Tibetan ethnicity, by nucleic acid MALDI-TOF.
Results: Polymorphisms of rs1065852, rs1135840 and rs16947 were significantly different between Han and Tibetan patients. rs1065852 AA genotype had a low frequency of 9.3% in Tibetan patients in comparison with a frequency of 41.7% in Han patients, whereas rs16947 AA genotype had a low frequency of 3.3% in Han patients in comparison with a frequency of 34.9% in Tibetan patients. Additionally, the two patient groups showed distinct distribution of CYP2D6 haplotypes, with the highest frequency of *10/*10 and *1/*2 in Han and Tibetan patients, respectively. Furthermore, Han and Tibetan patients showed differential CYP2D6 metabolic activity.
Discussion: Taken together, this exploratory study showed the differences of CYP2D6 gene and metabolic polymorphism between Han and Tibetan schizophrenia patients, and therefore may improve our understanding of the pharmacogenomic response to antipsychotics in schizophrenia patients across populations.
Keywords: CYP2D6; Han; Tibetan; schizophrenia.
© 2022 Li et al.
Conflict of interest statement
The authors declare that there is no conflict of interest involved in this work.
Similar articles
-
Genetic and epigenetic polymorphisms of eNOS and CYP2D6 in mainland Chinese Tibetan, Mongolian, Uygur, and Han populations.Pharmacogenomics J. 2020 Feb;20(1):114-125. doi: 10.1038/s41397-019-0104-2. Epub 2019 Oct 15. Pharmacogenomics J. 2020. PMID: 31616043
-
Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.Gene. 2013 Sep 15;527(1):360-5. doi: 10.1016/j.gene.2013.03.110. Epub 2013 May 3. Gene. 2013. PMID: 23644254
-
CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels.Pharmacogenet Genomics. 2019 Feb;29(2):39-47. doi: 10.1097/FPC.0000000000000363. Pharmacogenet Genomics. 2019. PMID: 30520769 Free PMC article.
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19817501 Review.
-
CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.Pharmacogenomics. 2007 Nov;8(11):1597-608. doi: 10.2217/14622416.8.11.1597. Pharmacogenomics. 2007. PMID: 18034624 Review.
Cited by
-
Genetic Variability of CYP4F2, CYP2D6, CYP2E1, and ACE in the Chinese Yi Population.Biochem Genet. 2025 Jun;63(3):2812-2830. doi: 10.1007/s10528-024-10748-y. Epub 2024 Jun 8. Biochem Genet. 2025. PMID: 38850376
References
LinkOut - more resources
Full Text Sources